Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment source : Www.anaptysbio.com save search
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial (Unedited, Advance Article)
Published: 2023-06-02 (Crawled : 17:00) - anaptysbio.com
ANAB | $19.84 -7.59% -8.32% 360K
|
Health Technology
|
| O: 0.38%
H: 1.35%
C: 0.92%
il-36 antibody treatment trial results
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
Published: 2023-03-28 (Crawled : 01:00) - anaptysbio.com
ANAB | $19.84 -7.59% -8.32% 360K
|
Health Technology
|
| O: 0.23%
H: 0.36%
C: -1.59%
treatment plus
Soluble BTLA (sBTLA) is Induced Following Targeting of BTLA In-vivo by ANB032, a Novel BTLA/HVEM Modulator Therapeutic Antibody for The Treatment of Autoimmune Disease
Published: 2022-11-08 (Crawled : 00:00) - anaptysbio.com
ANAB | $19.84 -7.59% -8.32% 360K
|
Health Technology
|
| O: 0.68%
H: 0.84%
C: -1.61%
anb032 treatment disease antibody
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial
Published: 2021-10-26 (Crawled : 20:00) - anaptysbio.com
ANAB | $19.84 -7.59% -8.32% 360K
|
Health Technology
|
| O: 5.47%
H: 2.32%
C: 0.23%
psoriasis treatment phase 2 results antibody trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.